Compare VYGR & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | UIS |
|---|---|---|
| Founded | 2013 | 1942 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.0M | 164.7M |
| IPO Year | 2015 | 1994 |
| Metric | VYGR | UIS |
|---|---|---|
| Price | $3.74 | $2.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $21.00 | $5.67 |
| AVG Volume (30 Days) | ★ 862.4K | 818.5K |
| Earning Date | 03-09-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,135,000.00 | ★ $1,950,100,000.00 |
| Revenue This Year | $54.19 | N/A |
| Revenue Next Year | $20.22 | $2.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.65 | $2.11 |
| 52 Week High | $5.55 | $5.33 |
| Indicator | VYGR | UIS |
|---|---|---|
| Relative Strength Index (RSI) | 42.89 | 43.64 |
| Support Level | $3.36 | $2.11 |
| Resistance Level | $3.74 | $2.65 |
| Average True Range (ATR) | 0.32 | 0.10 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 4.87 | 22.81 |
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. maximum of revenue is from CA&I segment.